Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. by Popp, J. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but dos not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Markers of neuroinflammation associated with Alzheimer's 
disease pathology in older adults. 
Authors: Popp J, Oikonomidi A, Tautvydaitė D, Dayon L, Bacher M, 
Migliavacca E, Henry H, Kirkland R, Severin I, Wojcik J, Bowman GL 
Journal: Brain, behavior, and immunity 
Year: 2017 Feb 1 
DOI: 10.1016/j.bbi.2017.01.020 
 
Accepted Manuscript
Markers of neuroinflammation associated with Alzheimer’s disease pathology
in older adults
Julius Popp, Aikaterini Oikonomidi, Domilė Tautvydaitė, Loïc Dayon, Michael
Bacher, Eugenia Migliavacca, Hugues Henry, Richard Kirkland, India Severin,
Jérôme Wojcik, Gene L. Bowman
PII: S0889-1591(17)30022-3
DOI: http://dx.doi.org/10.1016/j.bbi.2017.01.020
Reference: YBRBI 3079
To appear in: Brain, Behavior, and Immunity
Received Date: 14 October 2016
Revised Date: 15 January 2017
Accepted Date: 30 January 2017
Please cite this article as: Popp, J., Oikonomidi, A., Tautvydaitė, D., Dayon, L., Bacher, M., Migliavacca, E., Henry,
H., Kirkland, R., Severin, I., Wojcik, J., Bowman, G.L., Markers of neuroinflammation associated with
Alzheimer’s disease pathology in older adults, Brain, Behavior, and Immunity (2017), doi: http://dx.doi.org/10.1016/
j.bbi.2017.01.020
Markers of neuroinflammation associated with 
Alzheimer’s disease pathology in older adults 
Julius Popp1, *, Aikaterini Oikonomidi1, Domilė Tautvydaitė1, Loïc Dayon2, Michael Bacher3,
Eugenia Migliavacca2, Hugues Henry4, Richard Kirkland5, India Severin2, Jérôme Wojcik6, 
Gene L. Bowman2
1
2
3
4
5
6
CHUV, Old Age Psychiatry, Department of Psychiatry, Lausanne, 
Switzerland Nestlé Institute of Health Sciences, EPFL campus, Lausanne, 
Switzerland Philipps University of Marburg, Institute of Immunology, 
Marburg, Germany CHUV Department of Laboratories, Lausanne, 
Switzerland 
Prometheus Laboratories, San Diego, USA 
Quartz Bio, Geneva, Switzerland 
* Corresponding Author
Email: Julius.Popp@chuv.ch; 
Address: Old age psychiatry, Department of psychiatry, University hospital of Lausanne, 
Chemin de Mont-Paisible 16, CH-1011 Lausanne, Switzerland; Tel:  +41 (0)21 314 5151. 
Keywords: Alzheimer’s disease, mild cognitive impairment, neuroinflammation, biomarkers, 
amyloid, tau 
  
Abstract 
BACKGROUND: 
In vitro and animal studies have linked neuroinflammation to Alzheimer’s disease (AD) 
pathology. Studies on markers of inflammation in subjects with mild cognitive impairment or 
AD dementia provided inconsistent results. We hypothesized that distinct blood and 
cerebrospinal fluid (CSF) inflammatory markers are associated with biomarkers of amyloid 
and tau pathology in older adults without cognitive impairment or with beginning cognitive 
decline. 
OBJECTIVE: 
To identify blood-based and CSF neuroinflammation marker signatures associated with AD 
pathology (i.e. an AD CSF biomarker profile) and to investigate associations of inflammation 
markers with CSF biomarkers of amyloid, tau pathology, and neuronal injury. 
DESIGN/METHODS: 
Cross-sectional analysis was performed on data from 120 older community-dwelling adults 
with normal cognition (n = 48) or with cognitive impairment (n = 72). CSF Aβ1-42, tau and 
p-tau181, and a panel of 37 neuroinflammatory markers in both CSF and serum were 
quantified. Least absolute shrinkage and selection operator (LASSO) regression was applied 
to determine a reference model that best predicts an AD CSF biomarker profile defined a 
priori as p-tau181/Aβ1-42 ratio >0.0779. It was then compared to a second model that 
included the inflammatory markers from either serum or CSF. In addition, the correlations 
between inflammatory markers and CSF Aβ1-42, tau and p-tau181 levels were assessed. 
RESULTS: 
Forty-two subjects met criteria for having an AD CSF biomarker profile. The best predictive 
models included 8 serum or 3 CSF neuroinflammatory markers related to cytokine mediated 
inflammation, vascular injury, and angiogenesis. Both models improved the accuracy to 
  
predict an AD biomarker profile when compared to the reference model. In analyses 
separately performed in the subgroup of participants with cognitive impairment, adding the 
serum or the CSF neuroinflammation markers also improved the accuracy of the diagnosis of 
AD pathology. 
None of the inflammatory markers correlated with the CSF Aβ1-42 levels. Six CSF markers 
(IL-15, MCP-1, VEGFR-1, sICAM1, sVCAM-1, and VEGF-D) correlated with the CSF tau 
and p-tau181 levels, and these associations remained significant after controlling for age, sex, 
cognitive impairment, and APOEε4 status. 
CONCLUSIONS: 
The identified serum and CSF neuroinflammation biomarker signatures improve the accuracy 
of classification for AD pathology in older adults. Our results suggest that inflammation, 
vascular injury, and angiogenesis as reflected by CSF markers are closely related to cerebral 
tau pathology. 
  
1. Introduction
Neuroinflammation has long been known as an accompanying pathology of Alzheimer’s 
disease (AD). It is now well-established that localized low-level inflammation occurs early in 
the AD brain. In vitro and animal studies demonstrated the activation of different 
inflammatory pathways in association with amyloid pathology and tau-related 
neurodegeneration during the course of the disease. (Calsolaro and Edison, 2016; Heppner et 
al., 2015) In humans, genetic studies identified associations between polymorphisms in genes 
related to the immune system and the risk of AD (Calsolaro and Edison, 2016; Heneka et al., 
2015), while histopathological studies suggested that glial activation is an important mediator 
of neurotoxicity and altered cognition in the presence of amyloid and tau pathology (Perez-
Nievas et al., 2013). The inflammatory process driven by activated and proliferating glial cells, 
but also astrocytes, other myeloid cells, epithelium and other reactive elements leads to 
increased production and release of proinflammatory cytokines, chemokines and other 
mediators of inflammation. These factors may exacerbate amyloid production and toxicity, 
and contribute to tau hyperphosphorylation and neuronal injury. Vascular injury and 
endothelial dysfunction in relation to inflammation are also common in AD. They lead to the 
accumulation of several vasculotoxic and neurotoxic molecules within brain parenchyma, 
thus likely contributing to a noxious milieu finally promoting neuronal dysfunction and death 
(Grammas, 2011; Zlokovic, 2011). Several studies in subjects with mid cognitive impairment 
(MCI) and AD dementia revealed increased inflammatory activity in both the CNS and the 
circulating blood. However, reports on cytokines and other markers of inflammation in MCI 
or AD were controversial or inconsistent so far (Brosseron et al., 2014; Delaby et al., 2015; 
Hesse et al., 2016). 
The development of AD pathology starts many years before the onset of the first clinical signs. 
Older subjects with normal cognition may already have cerebral AD pathology and may be 
  
seen as being at the preclinical stage of the disease (Sperling et al., 2011). On the other hand, 
subjects with cognitive deficits may have cognitive impairment not primarily or only in part 
related to AD pathology. New research criteria consider AD as a biological continuum across 
the clinical spectrum from asymptomatic stage to advanced dementia, and emphasize the 
utility of biomarkers of AD pathology for an accurate diagnosis, in particular at the preclinical 
and prodromal disease stages (Albert et al., 2011; Dubois et al., 2014; Sperling et al., 2011). 
In this study, we aimed at identifying blood and cerebrospinal fluid (CSF) inflammation 
marker profiles related to the presence of cerebral AD pathology in older adults without 
cognitive impairment and with beginning cognitive decline. Furthermore, we hypothesized 
that blood and CSF inflammatory markers of cytokine mediated inflammation, vascular injury, 
and angiogenesis are associated with CSF biomarkers of amyloid and tau pathology. 
2. Material and Methods
2.1 Subjects 
One hundred and twenty community dwelling participants were included in this study, of 
whom 48 were cognitively healthy volunteers and 72 had mild cognitive impairment (MCI, 
N=63) or mild dementia of AD type (N=9). The participants with cognitive impairment were 
recruited among patients attending the Memory Clinic of the Old-Age Psychiatry service and 
the Leenaards Memory Centre of the Lausanne University Hospital. They had no major 
psychiatric or neurological disorders, nor substance abuse or severe or unstable physical 
illness that may contribute to cognitive impairment, and met the diagnostic criteria for MCI 
(Winblad et al., 2004) or mild dementia. The control subjects were recruited through journal 
announcements or word of mouth and had no history, symptoms, or signs of relevant 
psychiatric or neurologic disease and no cognitive impairment. All participants had a 
comprehensive medical, psychiatric, neuropsychological and psychosocial evaluation, as well 
  
as brain MRI or CT scans, and venous and lumbar punctures. The MRI and CT scans were 
used in order to exclude cerebral pathologies possibly interfering with the cognitive 
performance. 
The diagnosis of MCI or mild dementia of AD type was based on neuropsychological and 
clinical evaluation and was made by a consensus conference of neuropsychologists, 
psychiatrists, and/or neurologists prior to inclusion into the study. MCI was diagnosed 
according to consensus recommendations (Winblad et al., 2004). The participants in this 
group had memory impairment (<–1.5 standard deviation (SD) below the mean, adjusted for 
gender, age and education in the verbal memory task of Buschke Double Memory Test 
(Buschke et al., 1997a)) and/or impairment in another cognitive domain, and a Clinical 
Dementia Rating (CDR) (Morris, 1993) score of 0.5. The diagnosis of mild AD dementia was 
based on the clinical diagnostic criteria for probable dementia due to AD according to 
recommendations from the National Institute on Aging and Alzheimer’s Association 
(McKhann et al., 2011) and DSM-IV criteria for dementia of the Alzheimer type (American-
Psychiatric-Association, 1994). Participants in this group had a CDR score of 1. The subjects 
with MCI and mild dementia were considered as one group with CDR>0). The participants 
without cognitive impairment had no history or evidence of cognitive deficits, and their CDR 
score was 0. 
Neuropsychological tests were used to assess cognitive performance in the domains of 
memory -Buschke Double Memory Test (Buschke et al., 1997b), language -a verbal fluency 
task (categorical and literal fluency in 2 min)executive functions: a speed of  processing and 
cognitive flexibility task - the Trail Making Test A and B (Reitan, 1958),  an inhibition task - 
the Stroop test (Bayard et al., 2009), and visuo-constructive functions (CERAD copy image 
test). The Mini Mental State Examination (Folstein et al., 1975) was used to assess 
participants’ global cognitive performance. Depression and anxiety were assessed using the 
Hospital Anxiety and Depression scale (HAD) (Zigmond and Snaith, 1983). The psychosocial 
and functional assessment included the ADL (Katz, 1997) and instrumental ADL (Lawton 
and Brody, 1970), the NPIQ (Cummings et al., 1994) and the IQCODE (Jorm and Jacomb, 
1989) questionnaires and were completed by the family members of the participants. All tests 
and scales are validated and widely used in the field. 
The study was approved by the local ethics committee and written informed consent to 
participate in the study was obtained from all participants. 
2.2 Cerebrospinal fluid AD biomarkers and APOE genotyping 
Venous and lumbar punctures were performed between 8:30 and 9:30 am after overnight 
fasting at the recruiting memory centre. CSF was collected by lumbar puncture, using a 
standardized technique with a 22G “atraumatical” spinal needle while the patient was sitting 
or lying (Popp et al., 2007). Ten to twelve ml of CSF were obtained using polypropylene 
tubes. Routine cell count and protein quantification were performed. Remaining CSF and 
blood was frozen in aliquots no later than 1 h after collection and stored at -80 °C without 
thawing until assay. CSF Aβ1-42, total-tau (tau), and tau phosphorylated at threonine 181 
(ptau181) concentrations were measured using commercially available ELISA kits (Fujirebio, 
Gent, Belgium). The APOE genotype was determined and considered in all main analytical 
steps to evaluate possible interactions and effects on the addressed relationships (Jansen et al., 
2015; Popp et al., 2010). DNA was extracted from whole blood using the QIAsymphony DSP 
DNA Kit (Qiagen, Hombrechtikon, Switzerland). The SNV rs429358 and rs7412 were 
genotyped using the Taqman assays C___3084793_20 and C____904973_10 respectively 
(Thermo Fischer Scientific, Waltham, MA, USA). 
A pathological CSF AD biomarker profile was defined as a p-tau181/Aβ1-42 ratio >0.0779, 
based on clinical study site data (Tautvydaite et al., 2016) and in line with previous 
  
publications (Duits et al., 2014). Briefly, the cutoff was determined from 48 healthy 
volunteers with normal cognition and 72 memory clinic patients with MCI or mild dementia 
of AD type as the value that optimized the Youden index of the Received Operating 
Characteristic (ROC) curve of prediction of CDR categories (CDR = 0 vs. CDR > 0; 
AUC=0.789, accuracy: 0.733). This cutoff was further confirmed to be a highly significant 
predictor of cognitive decline (i.e. change in global cognition as measured by MMSE at a 
follow-up visit 18 months after inclusion) in models adjusted for multiple possible 
confounders (Beta=-0.436; p<0.00001; unpublished data) 
2.3 Neuroinflammatory markers 
Paired serum and CSF samples were measured using the V-Plex Neuroinflammation Panel 1 
(Meso Scale Discovery (MSD), Rockville, MD, USA). The Panel consisting of 38 analytes 
was run according to product protocol. The 96-well plates pre-coated with capture antibodies 
were blocked with 5% MSD Blocker A Solution. Calibrator dilutions were prepared and 
samples were diluted as recommended for each kit with MSD Diluents. Samples and 
calibrators were then added to the plates and incubated at room temperature with shaking for 
2 h. Plates were washed three times with a home-prepared solution of 10 × phosphate-
buffered saline (PBS), pH 7.4 (Corning, VA, USA)-Tween 20 (Fisher Scientific, PA, USA). 
Detection antibodies were mixed with MSD Diluents as indicated in the protocols of each kit 
and incubated at room temperature with shaking for 1-2 h. Plates were washed three times 
with the PBS-Tween 20 solution. MSD Read buffer was added and plates were read on an 
MSD instrument (SECTOR Imager 6000 reader). Data were generated and interpolated using 
MSD Discovery Workbench software. 
2.4 Pre-analytical quality controls and filtering 
  
Biomarkers with more than 5% missing data or below-level-of-quantification limits were 
filtered out, ending up with a selection of 37 analytes: IFNγ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-
10, IL-13, TNFα, IL-1α, IL-5, IL-7, IL-12/23p40, IL-15, IL-16, IL-17A, TNFβ, VEGF-A, 
Eotaxin, MIP-1β, Eotaxin-3, TARC, IP-10, MIP-1α, MCP-1, MDC, MCP-4, VEGF-C, 
VEGF-D, Tie-2, sFLT-1 (VEGFR-1), pIGF-1R, bFGF (FGF-2), SAA1, CRP, sVCAM-1, and 
sICAM-1. IL-12p70 was not included. Remaining missing data (5% or less per biomarker) 
were imputed by randomly drawing a measure between in the observed range of biomarker 
values. Biomarker data was log10-transformed to approach a Gaussian distribution, and 
standardized prior to statistical analyses. One low quality CSF sample and two serum samples 
could not be analyzed. Therefore serum and CSF neuroinflammatory biomarker data were 
available for 118 and 119 subjects, respectively. 
2.5 Statistical analyses 
Least absolute shrinkage and selection operator (LASSO) logistic regression (Tibshirani, 
1996) was used to select relevant biomarker features and build a predictive model of AD CSF 
biomarker profiles. All biomarker variables were included in the model, together with the 
variables used in a reference model (age, sex, years of education, and presence of APOE ε4 
allele) that was tested independently. CSF and serum biomarkers were tested separately. A 
10-fold cross-validation process was performed for each LASSO analysis using the glmnet 
package (Friedman et al., 2010), which permitted to estimate the confidence interval of the 
misclassification error for each value of the regularization parameter. The LASSO analysis 
was repeated 100 times. The model that minimized the cross-validated misclassification error 
across the 100 runs was selected. Its performance was assessed by ROC AUC estimation 
(using a bootstrap approach with 1000 iterations) and compared with the reference model 
AUC and accuracy (using a McNemar test). 
  
Two-sided correlation analyses between neuroinflammatory biomarkers and AD CSF markers 
(Aβ1-42, tau and p-tau181) were performed with the Pearson’s statistics and resulting p-
values were adjusted for multiple-testing using Bonferroni correction. 
Neuroinflammatory markers significantly (p < 0.05) correlated with an AD CSF marker 
(Aβ42, tau or p-tau181) were further studied in a linear regression model with the AD CSF 
marker as the dependent variable and the following list of explanatory covariates: each 
neuroinflammatory marker, age (in years), sex (categorical:  male vs. female), APOE ε4 status 
(categorical, presence vs. absence of at least one ε4 allele), CDR (categorical: >0, i.e. subjects 
with MCI and mild dementia considered as one group vs. 0), and albumin quotient (only for 
serum neuroinflammatory biomarkers). Values of the regression terms were reported and their 
differences from 0 were assessed with t-tests. Interaction terms between the 
neuroinflammatory markers and separately age, sex, CDR, and APOE ε4 status were further 
tested in a type II Analysis of Variance (ANOVA) with a F-test. 
3. Results
Demographics and clinical characteristics of the patient cohort are detailed in Table 1. 
Participants with cognitive impairment (CDR > 0) were significantly older than subjects with 
normal cognition (CDR = 0). 
Table 1 – Demographics and clinical characteristics 
CDR = 0 
(n = 48) 
CDR > 0 
(n = 72) 
Age (years), mean (SD) 66.0 (7.4) 73.3 (6.9)* 
Gender, No. (%) of Males 17 (35.42%) 26 (36.11%) 
Education years, mean (SD) 13.2 (2.3) 11.8 (2.7)* 
MMSE scale, mean (SD) 28.5 (1.4) 25.9 (3.5)* 
APOEε4 carriers, No. (%) 11 (22.92%) 26 (36.11%)* 
CSF Aβ 1-42 (pg/mL), mean (SD) 957.4 (194.0) 774.0 (281.5)* 
CSF tau (pg/mL) , mean (SD) 221.5 (82.9) 471.1 (316.6)* 
CSF p-tau181 (pg/mL), mean (SD) 45.9 (13.3) 72.7 (40.9)* 
p-tau/Aβ 1-42, mean (SD) 0.049 (0.015) 0.114 (0.097)* 
AD CSF biomarker profile, No. (%) 1 (2.08%) 41 (56.94%)* 
Albumin ratio, mean (SD) 5.3 (1.9) 6.6 (2.5)* 
*statistically different (p ≤ 0.05) from CDR 0, using t-tests for continuous variables and
binomial proportion tests for categorical variables. 
APOEε4 = Apolipoprotein E ε4 allele; MMSE = Mini Mental State Examination 
The reference LASSO classifier generated an accuracy of 78.3% and a ROC AUC of 0.83 
[0.74 - 0.90]. The LASSO analyses performed by adding the inflammatory markers, 
separately CSF and serum, outperformed the reference classifier significantly in terms of 
accuracy but not in terms of AUC. The model including the serum inflammatory markers 
generated an accuracy of 86.4% (p = 0.01) and ROC AUC 0.89 [0.81 – 0.95] (p = 0.14, 
Figure 1a). Eight serum biomarkers were selected in this predictive model: bFGF, CRP, IL-16, 
sFLT-1, sICAM-1, Tie-2, VEGF-C, and VEGF-D (Figure 2a). The CSF neuroinflammatory 
model had an accuracy of 85.7% (p = 0.02 as compared with the reference model) and ROC 
AUC 0.90 [0.83 – 0.95] (p = 0.08, Figure 1b). Three biomarkers were selected in this 
predictive model: IL-15, MCP-1, and sFLT-1 (VEGFR-1) (Figure 2b). When performed in 
the 72 subjects with cognitive impairment only (CDR > 0), the model including the serum 
inflammatory markers had an accuracy of 91.7% (p = 0.02) as compared with the reference 
model in this sub-population (accuracy of 77.8%) and ROC AUC 0.96 [0.89 – 0.99] (p < 0.01, 
Supplementary Figure a). The corresponding CSF neuroinflammatory model had an accuracy 
of 90.3% (p = 0.07) and AUC 0.93 [0.85 - 0.97] (vs. reference model ROC AUC 0.83 [0.73 – 
0.91], p = 0.04 (Supplementary Figure b). 
(a) 
(b) 
Figure 1 – ROC curves of the serum (a) and CSF (b) models predictive of biomarker 
CSF profile. 
The ROC curves of the LASSO models including neuroinflammatory biomarkers (in red) are 
compared with the ROC curves of the reference LASSO models (in blue). The opacity of the 
curves is proportional to the accuracy of the models. The diamonds indicate the selected most 
accurate models. The p-values on the graphs indicate the significance of the differences of 
AUC. The biomarkers models had a ROC AUC of 0.89 [0.81 - 0.95] in serum and of 0.90 
[0.83 - 0.95] in CSF. 
 (a) 
(b) 
Figure 2. Frequencies of selected markers in all LASSO models. 
The LASSO analyses were repeated 100 times, each time selecting possibly different 
biomarkers. The histograms display the frequencies of most frequent (>10%) selected markers 
in serum (a) and CSF (b) models. The biomarkers retained in final best models are bFGF, 
CRP, IL-16, sFLT-1, sICAM-1, Tie-2, VEGF-C, VEGF-D in serum, and IL-15, MCP-1, 
sFLT-1 in CSF. 
The 37 neuroinflammatory biomarkers, either in CSF or serum, were analyzed for correlation 
with CSF Aβ1-42, tau or p-tau181. No significant correlation was observed with Aβ1-42 after 
correction for multiple testing. Six CSF inflammatory markers were correlated with both CSF 
tau and p-tau181: IL-15, MCP-1, VEGFR-1/ sFLT-1, sICAM1, sVCAM-1, VEGF-D, 
together with serum IL-8 correlated with CSF p-tau181 (Table 2). Correlations of the 6 CSF 
inflammatory biomarkers with CSF tau are illustrated in Figure 3). 
Table 2 – Neuroinflammatory biomarkers significantly correlated with AD CSF 
markers. 
Tissue Biomarker r2 (p-value) 
vs. CSF tau vs. CSF p-tau181 
CSF IL-15 0.26 (2e-9) 0.24 (1e-8) 
MCP-1 0.16 (6e-6) 0.14 (2e-5) 
sFLT-1 0.37 (1e-13) 0.32 (3e-11) 
sICAM-1 0.22 (1e-7) 0.16 (6e-6) 
sVCAM-1 0.26 (4e-9) 0.20 (4e-7) 
VEGF-D 0.18 (2e-5) 0.14 (2e-4) 
serum IL-8 not significant 0.09 (9e-4) 
Figure 3 – Correlations between CSF neuroinflammatory and CSF tau. 
Correlation of six CSF neuroinflammatory biomarkers (log10-transformed concentrations, in 
pg/mL) with CSF tau (log10-transformed concentrations, in pg/mL). Each dot represents a 
subject. The blue line represents the linear fit, and the gray shading its confidence interval. 
The results of the linear regression models with CSF tau and CSF p-tau181 as dependent 
variables are summarized in Table 3 a.  and 3 b respectively. The cognitive impairment status 
term (CDR = 0 vs. CDR > 0) was found associated in all models, confirming the association 
of high expression levels of CSF tau with cognitive impairment. Interaction terms between 
biomarker and age, sex, CDR, and APOE ε4 status were then added to the regression models 
and tested in an ANOVA. The only significant interaction was found between CDR category 
  
and sFLT-1, where the correlation between CSF sFLT-1 and tau was stronger in the CDR > 0 
category than in the CDR = 0 category (p = 0.04). The F-value of the CDR x sFLT-1 
interaction term is 4.44 (df=1). The correlation in the CDR 0 group is r = 0.43 (r2 = 0.19, p = 
0.002) vs. r = 0.67 (r2 = 0.44, p = 1.7e-10) in the CDR >0 group. No other interactions were 
identified. 
Table 3a – Regression coefficients in linear model with CSF tau as dependent variable. 
Regression term IL-15 MCP-1 sFLT-1 sICAM-1 sVCAM-1 VEGF-D 
Inflammation 
marker 
1.406 *** 0.702 *** 1.171 *** 0.839 *** 1.006 *** 0.470 *** 
Age 0.001 0.006 0.007 ** 0.005 0.004 0.008 ** 
Sex 0.007 -0.009 -0.057 0.007 0.023 -0.004 
APOEε4 status 0.125 ** 0.058 0.099 * 0.100 * 0.103 * 0.089 
CDR category 0.150 *** 0.183 *** 0.129 ** 0.140 ** 0.157 *** 0.174 *** 
intercept 1.455 *** 0.083 -0.131 -0.817 -1.876 ** 1.008 *** 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
Table 3b – Regression coefficients in linear model with CSF p-tau181 as dependent 
variable. 
Regression term IL-15 MCP-1 sFLT-1 sICAM-1 sVCAM-1 VEGF-D 
Inflammation 
marker 
0.957 *** 0.396 ** 0.836 *** 0.610 *** 0.667 *** 0.375 *** 
Age 0.000 0.004 0.004 * 0.002 0.002 0.005 * 
Sex -0.004 -0.016 -0.049 -0.003 0.006 -0.010 
APOEε4 status 0.060 * 0.018 0.043 0.044 0.046 0.036 
CDR category 0.100 ** 0.122 *** 0.083 ** 0.090 * 0.105 ** 0.114 ** 
  
intercept 1.112 *** 0.363 -0.028 -0.550 -1.092 * 0.730 *** 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
4. Discussion
We identified serum and CSF inflammation biomarker signatures associated with the 
presence of core AD pathology in older adults with normal cognition and cognitive 
impairment. The selected inflammatory biomarkers from serum (bFGF, CRP, IL-16, sFLT-1, 
sICAM-1, Tie-2, VEGF-C, and VEGF-D) and, separately, from CSF (IL-15, MCP-1, and 
sFLT-1) significantly improved the accuracy of classification for AD pathology, in particular 
in subjects with cognitive impairment. Furthermore, the CSF concentrations of six 
neuroinflammation markers (IL-15, MCP-1, sFLT-1, sICAM-1, sVCAM-1) were associated 
with the CSF tau and p-tau181 levels after controlling for several possible confounders. 
Applying an approach unbiased by the clinical diagnosis, we identified distinct inflammatory 
biomarker signatures in serum and CSF associated with the presence of “core” AD pathology 
i.e. the combined presence of cerebral amyloid and tau pathology. The differences observed 
between the serum and CSF inflammatory profiles, while considering the blood-brain-barrier 
function, support the hypothesis that peripheral inflammatory activity related to AD may be at 
least partially independent of inflammation in the CNS. As it is based on an easily accessible 
tissue, the serum inflammatory marker signature may be particularly helpful for early non-
invasive screening for elderly subjects at risk of cognitive decline related to AD at pre-
dementia and prodromal disease stages. While an unbiased classification based on markers of 
cerebral amyloid, tau pathology, and neuronal injury can be used across the clinical stages 
(Jack et al., 2016), our results suggest that the inflammatory biomarker signatures may be 
particularly useful in the subjects with cognitive impairment. In the subgroup with MCI and 
mild dementia, adding the CSF and serum inflammation markers to the demographic metrics 
  
improved the accuracy more markedly (by 12.5% and 13.9%, respectively; see also the 
Supplementary Figure) than in the participants with and without cognitive impairment 
considered together (improvement by 7.4% and 8.1%, respectively). Also, the differences 
between the AUC were significant when performed in the subgroup with cognitive 
impairment, but not in the whole sample of participants. These findings suggest that 
inflammatory biomarker signatures may improve the diagnostic accuracy of cerebral AD 
pathology underlying cognitive impairment in MCI and mild dementia. Independent 
validation is needed to evaluate their usefulness in clinical settings. 
Addressing the relationships between inflammatory markers and amyloid and tau pathology, 
we found six CSF neuroinflammation markers to be correlated with CSF tau and ptau 
independently of age, gender, cognitive status, and APOEe4 status. None of the included 
inflammation marker was correlated with CSF Aβ1-42 levels. 
Enhanced expression of mediators of inflammation has been previously described in the 
vicinity of amyloid plaques suggesting increased inflammatory activity as a consequence of 
accumulating amyloid pathology (Bacher et al., 2010; Calsolaro and Edison, 2016). 
Furthermore, sustained neuroinflammation may contribute to the development of amyloid 
pathology by stimulating the expression of inflammatory mediators that have been shown to 
increase amyloid precursor protein and amyloid production (Heneka et al., 2015; Popp et al., 
2009). Cerebral amyloid accumulation was shown to increase under inflammatory conditions 
in animals (Calsolaro and Edison, 2016). However, recent studies have found that, while glial 
inhibition or depletion may prevent neuronal loss, it may have no substantial effects on 
cerebral amyloid accumulation (Coma et al., 2010; Spangenberg et al., 2016) suggesting that 
amyloid production in AD may much more depend on other mechanisms. Also, a few studies 
assessing single inflammation markers in the CSF have found significant associations of these 
markers with Aβ1-42 levels in subjects with normal Aβ1-42 only (Alcolea et al., 2015; 
  
Henjum et al., 2016). In line with these studies, we observed no correlation between 
inflammation markers and the CSF Aβ1-42 levels. 
Evidence from animal AD models suggests that both localized microglia activation related to 
cerebral amyloid pathology and CNS inflammatory response to systemic inflammation can 
exacerbate the development of tau pathology and may correlate with the spread of 
pathological tau in the brain (Ghosh et al., 2013; Kitazawa et al., 2005; Maphis et al., 2015) 
(Lee et al., 2010),(Fang et al., 2016). Microglial activation precedes the development of tau 
pathology while early immunosuppression in tau transgenic mice results in attenuated tau 
pathology, reduced neuronal and synaptic loss, and increased lifespan (Jiang et al., 2016; 
Yoshiyama et al., 2007). Also, studies using different models of immune deficiency in AD 
transgenic mice found reduced tau hyperphosphorylation in relation to suppressed 
inflammatory activity (Li, Yu et al. 2015). 
Among the markers of neuroinflammation included in our study, one serum marker (IL-8) 
was associates with the CSF ptau and six CSF markers (IL-15, MCP-1, sFLT-1, sICAM-1, 
sVCAM-1) were associated with the CSF ptau and tau levels suggesting the implication of 
these molecules in tau hyperphosphorylation and neuronal injury. IL-8 is a chemokine and 
angiogenesis promoter produced by macrophages but also by other cell types such as 
epithelial and endothelial cells. IL-8 has been reported to be increase in plasma and CSF of 
patients with clinically diagnosed AD (Wennstrom et al., 2015), but other studies found no 
association (Delaby et al., 2015; Swardfager et al., 2010) or even decreased levels (Hesse et 
al., 2016) in AD dementia. In our study we observed only a relatively weak association the 
serum IL-8 with p-tau181 levels after controlling for confounders. IL-15 is a pro-
inflammatory cytokine which was shown to promote microglial activation through the NFκB, 
p38, and ERK1⁄2 pathways, thereby enhancing the production of pro-inflammatory cytokines 
and growth factors (Gomez-Nicola et al., 2010). IL-15 also regulates T and B lymphocyte 
  
activity and displays neurotrophic, anti-apoptic and pro-neurogenesis effects (Bishnoi et al., 
2015). Lower serum IL-15 levels were found in patients with AD compared to healthy 
subjects and to subjects with vascular dementia (Rentzos et al., 2007), while in the CSF 
higher IL-15 concentrations have been observed in subjects with AD and fronto-temporal 
dementia compared to patients with non-inflammatory neurological disorders (Rentzos et al., 
2006). 
MCP-1 is a key chemokine involved in monocyte/macrophage migration during inflammatory 
processes, which can be produced by different cell types including astrocytes and microglia 
(Barber et al., 2015; Deshmane et al., 2009). MCP-1 serum and CSF levels have been 
reported to be increased in MCI and AD dementia (Galimberti et al., 2006a; Galimberti et al., 
2006b). 
Cell Adhesion Molecules (CAMs), including sVCAM-1 and sICAM-1 may be considered as 
biomarkers of endothelial dysfunction in AD (Grammas, 2011; Huang et al., 2015). While 
VCAM-1 is expressed only by endothelial cells, ICAM-1 is also expressed by leukocytes and 
astrocytes (Huang et al., 2015; Rentzos et al., 2004) and it has been found within amyloid 
plaques (Verbeek et al., 1994). Levels of both VCAM-1 and ICAM-1 have been reported to 
be elevated in patients with clinically diagnosed AD dementia (Huang et al., 2015; Rentzos et 
al., 2004). 
VEGF is a family of molecules that bind to tyrosine kinase receptors such as VEGFR-1/ 
sFLT-1, and play a key role in angiogenesis, but also in promoting neurogenesis in the dentate 
gyrus in the hippocampus (Carmeliet and Storkebaum, 2002; Dal Pra et al., 2014). CSF 
VEGF levels have been previously found to be elevated among patients with AD dementia 
(Tarkowski et al., 2002). VEGF is expressed by neurons, microglia, astrocytes and endothelial 
cells, and was found within diffuse perivascular amyloid plaques in the brains of patients with 
AD (Merrill and Oldfield, 2005; Thirumangalakudi et al., 2006). It has been hypothesized that 
  
VEGF is secreted following stimulation by Aβ and may indicate a compensatory mechanism 
for the compromised vasculature and perfusion in the AD brain (Patel et al., 2010) (Salomon-
Zimri et al., 2016). 
In this context, our findings of highly significant correlations between CSF ptau181 and tau 
levels, and six CSF markers of cytokine mediated inflammation, vascular injury, and 
angiogenesis support the hypothesis that increased cerebral inflammatory activity and 
microvascular pathology may contribute to tau hyperphosphorylation and neuronal injury in 
AD. While further studies including experimental approaches are needed to understand the 
precise underlying mechanisms, our results suggest that specific neuroinflammatory processes 
indicated by these markers could represent therapeutic targets in the future to prevent or slow 
down the development of tau pathology and neurodegeneration in early AD. The preliminary 
findings on associations between some inflammatory markers and global cognitive 
performance further suggest that inflammation may be related to the severity of cognitive 
impairment in MCI and mild dementia. 
Strengths of this study are the large panel of markers known to play a role in the immune 
response in the CNS including cytokines, chemokines and markers of inflammation related to 
vascular injury and angiogenesis. Further, the parallel assessment of both blood and CSF 
markers of inflammation in the same participants while considering BBB function provides 
insights on the relationships between peripheral and CNS inflammation associated to AD 
pathology. 
A limitation of this study is the lack of longitudinal biomarker measures and the non-inclusion 
of more severe dementia cases. Some of the measured inflammatory markers might increase 
steadily during disease progression or temporarily at the pre-clinical and early clinical disease 
stages (Calsolaro and Edison, 2016). The identified signatures might be specific for early 
stage AD, and may differ from signatures in more advanced clinical stages, or from signatures 
  
associated with a rapid cognitive decline. While the primary aim of this study was to identify 
serum and CSF inflammation markers associated with core AD pathology, the results suggest 
that the identified inflammatory signatures may represent useful markers to improve diagnosis 
accuracy and prediction of further cognitive decline. The serum inflammatory marker 
signature of AD may be particularly helpful for early non-invasive screening for elderly 
subjects at risk of developing AD dementia and for identifying potential participants for 
targeted interventions at pre-dementia disease stages. Further studies including longitudinal 
follow-up and independent sample validation are needed to address these aspects. 
Together, the results of this study provide evidence that inflammation is part of the AD 
pathology at early clinical stages. Specific combinations of serum and CSF inflammation 
markers improve prediction of cerebral AD pathology in older adults, in particular in subjects 
with cognitive impairment. Independent sample validation and longitudinal clinical follow-up 
are needed to evaluate the usefulness of inflammatory biomarker signatures in clinical settings. 
Cytokine mediated inflammation, vascular injury, and angiogenesis as reflected by CSF 
markers are closely related to markers of cerebral tau pathology suggesting involvement in 
tau hyperphosphorylation and neuronal injury. These relationships may represent potential 
intervention targets to reduce neurodegeneration in AD. 
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Supplementary table 1 
Demographics and biochemical markers by CSF profile categories. 
All 
(n = 120) 
Non-AD CSF 
biomarker 
profile (n=78) 
AD CSF 
biomarker 
profile (n=42) 
Age (years), mean (SD) 70.4 (7.9) 68.4 (8.3) 74.1 (5.6)* 
Gender, No. (%) of Males 43 (35.83%) 25 (32.05%) 18 (42.86%) 
Education years, mean (SD) 12.4 (2.6) 12.5 (2.7) 12.1 (2.4) 
MMSE scale, mean (SD) 26.9 (3.1) 27.8 (2.3) 25.2 (3.7)* 
APOE ε4 carriers, No. (%) 37 (30.83%) 13 (16.67%) 24 (57.14%)* 
CSF Aβ 1-42 (pg/mL), mean (SD) 847.4 (265.1) 979.9 (196.4) 601.2 (190.0)* 
CSF p-tau181 (pg/mL), mean (SD) 62.0 (35.2) 46.7 (13.4) 90.3 (44.8)* 
CSF tau (pg/mL), mean (SD) 371.3 (278.6) 235.1 (104.2) 624.2 (322.4)* 
Albumin ratio, mean (SD) 6.1 (2.4) 5.9 (2.4) 6.4 (2.3) 
Inflammation markers in serum 
BFGF (pg/mL), mean (SD) 4.5 (4.7) 4.7 (4.8) 4.2 (4.4) 
CRP (µg/mL), mean (SD) 2.5 (4.1) 2.7 (3.8) 2.1 (4.6) 
Eotaxin (pg/mL), mean (SD) 169.6 (68.2) 166.4 (67.0) 176.5 (71.7) 
Eotaxin-3 (pg/mL), mean (SD) 37.6 (37.9) 32.1 (15.4) 49.6 (62.7) 
IFNγ (pg/mL), mean (SD) 10.2 (12.6) 9.8 (13.4) 10.8 (11.1) 
IL-12/IL-23p40 (pg/mL), mean (SD) 161.8 (77.5) 156.1 (79.5) 172.1 (73.5) 
IL-15 (pg/mL), mean (SD) 3.0 (0.6) 3.0 (0.6) 3.0 (0.7) 
IL-16 (pg/mL), mean (SD) 227.7 (72.7) 231.5 (80.7) 220.8 (55.7) 
  
IL-6 (pg/mL), mean (SD) 4.9 (44.0) 0.8 (0.6) 12.4 (73.8) 
IL-7 (pg/mL), mean (SD) 29.3 (9.9) 29.8 (10.4) 28.6 (9.0) 
IL-8 (pg/mL), mean (SD) 15.3 (7.7) 14.8 (5.2) 16.1 (10.8) 
IP-10 (pg/mL), mean (SD) 375.0 (239.5) 360.5 (221.8) 406.3 (276.3) 
MCP-1 (pg/mL), mean (SD) 343.0 (130.7) 339.5 (133.0) 350.6 (127.8) 
MCP-4 (pg/mL), mean (SD) 179.8 (90.3) 183.7 (94.9) 171.5 (80.6) 
MDC (pg/mL), mean (SD) 1022.9 (313.8) 1073.6 (345.8) 913.3 (193.9)* 
MIP-1α (pg/mL), mean (SD) 24.0 (10.6) 23.6 (11.4) 24.9 (8.6) 
MIP-1β (pg/mL), mean (SD) 109.2 (51.5) 114.8 (50.9) 97.3 (51.8) 
pIGF-1R (pg/mL), mean (SD) 28.3 (7.4) 27.4 (6.7) 29.8 (8.2) 
SAA (µg/mL), mean (SD) 7.6 (19.5) 9.2 (23.9) 4.8 (4.5) 
sFLT-1 (pg/mL), mean (SD) 114.9 (35.1) 112.0 (38.3) 120.2 (28.1) 
sICAM-1 (ng/mL), mean (SD) 372.2 (89.4) 379.1 (89.8) 359.7 (88.2) 
sVCAM-1 (ng/mL), mean (SD) 576.2 (130.4) 572.8 (134.6) 582.3 (123.9) 
TARC (pg/mL), mean (SD) 267.1 (185.8) 263.0 (183.7) 276.0 (193.9) 
Tie-2 (ng/mL), mean (SD) 6.3 (1.6) 6.5 (1.6) 6.1 (1.7) 
TNF α (pg/mL), mean (SD) 2.9 (1.1) 3.0 (1.3) 2.8 (0.7) 
VEGF (pg/mL), mean (SD) 142.5 (114.4) 148.2 (106.1) 132.2 (128.9) 
VEGF-C (pg/mL), mean (SD) 511.9 (168.9) 523.7 (163.5) 490.7 (178.1) 
VEGF-D (pg/mL), mean (SD) 813.6 (268.1) 760.8 (211.3) 909.1 (330.1)* 
Inflammation markers in CSF 
CRP (ng/mL), mean (SD) 7.2 (14.1) 7.9 (12.8) 6.0 (16.3) 
IL-12/IL-23p40 (pg/mL), mean (SD) 5.8 (2.1) 5.8 (2.3) 5.6 (1.5) 
IL-15 (pg/mL), mean (SD) 3.8 (1.0) 3.6 (1.0) 4.2 (0.9)* 
  
IL-16 (pg/mL), mean (SD) 13.2 (5.1) 13.0 (3.6) 13.7 (7.1) 
IL-6 (pg/mL), mean (SD) 1.2 (0.9) 1.2 (0.8) 1.3 (1.0) 
IL-7 (pg/mL), mean (SD) 1.4 (0.6) 1.4 (0.6) 1.5 (0.6) 
IL-8 (pg/mL), mean (SD) 41.9 (14.7) 39.9 (9.1) 45.4 (21.1) 
IP-10 (pg/mL), mean (SD) 596.2 (320.5) 601.7 (361.9) 586.1 (229.7) 
MCP-1 (pg/mL), mean (SD) 453.4 (135.7) 423.7 (121.6) 507.8 (144.6)* 
MCP-4 (pg/mL), mean (SD) 5.4 (3.3) 5.0 (3.2) 6.0 (3.3) 
MDC (pg/mL), mean (SD) 33.4 (21.4) 34.5 (22.8) 31.5 (18.9) 
MIP-1α (pg/mL), mean (SD) 20.6 (6.6) 20.2 (6.6) 21.4 (6.6) 
MIP-1β (pg/mL), mean (SD) 14.4 (4.5) 14.4 (4.8) 14.6 (3.7) 
pIGF-1R (pg/mL), mean (SD) 80.2 (29.6) 76.1 (29.0) 87.7 (29.4)* 
SAA (ng/mL), mean (SD) 2.0 (5.8) 2.2 (7.0) 1.4 (1.8) 
sFLT-1 (pg/mL), mean (SD) 60.3 (19.1) 54.1 (15.3) 71.7 (20.4)* 
sICAM-1 (ng/mL), mean (SD) 2.4 (0.7) 2.3 (0.7) 2.6 (0.5)* 
sVCAM-1 (ng/mL), mean (SD) 8.4 (2.8) 7.9 (2.5) 9.3 (3.1)* 
TARC (pg/mL), mean (SD) 4.0 (2.2) 4.0 (2.4) 4.2 (1.9) 
VEGF (pg/mL), mean (SD) 4.3 (1.0) 4.2 (0.9) 4.3 (1.1) 
VEGF-D (pg/mL), mean (SD) 44.3 (17.2) 41.5 (15.9) 49.5 (18.4)* 
*statistically different (p ≤ 0.05) from the group with Non-AD CSF profile, using t-tests for
continuous variables and binomial proportion tests for categorical variables. 
APOEε4 = Apolipoprotein E ε4 allele; MMSE = Mini Mental State Examination 
Supplementary table 2 
Correlation between neuroinflammatory markers and MMSE in cognitively impaired 
subjects. 
Biomarker 
Serum CSF 
r r
2 p r r2 p 
BFGF 0.1943 0.03775 0.1097 NA NA NA 
CRP -0.1983 0.03933 0.09493 -0.2839 0.08058 0.01567 
Eotaxin -0.2353 0.05537 0.1197 NA NA NA 
Eotaxin-3 0.02923 0.0008544 0.8636 NA NA NA 
IFNγ -0.04643 0.002156 0.7006 NA NA NA 
IL-12/IL-23p40 -0.1447 0.02092 0.2254 -0.2464 0.06072 0.03693 
IL-15 -0.2275 0.05174 0.05642 -0.1131 0.01279 0.3443 
IL-16 -0.2652 0.07033 0.02436 -0.3884 0.1509 0.0007468 
IL-6 0.002301 5.294e-06 0.9886 0.07275 0.005293 0.5465 
IL-7 0.03365 0.001133 0.779 0.1058 0.01119 0.4555 
IL-8 -0.3079 0.09478 0.008516 -0.1044 0.0109 0.3828 
IP-10 0.2255 0.05087 0.1363 -0.1981 0.03926 0.09524 
MCP-1 0.05224 0.002729 0.7333 -0.101 0.01019 0.3988 
MCP-4 -0.1211 0.01465 0.4283 0.07942 0.006307 0.6502 
MDC 0.06647 0.004418 0.6644 0.02707 0.0007327 0.8978 
Biomarker 
Serum CSF 
r r2 p r r2 p 
MIP-1α 0.1861 0.03462 0.2921 -0.224 0.05016 0.07521 
MIP-1β 0.05514 0.00304 0.719 0.0443 0.001963 0.7117 
pIGF-1R 0.1275 0.01625 0.2859 -0.211 0.04452 0.07523 
SAA -0.03499 0.001224 0.7704 -0.3402 0.1157 0.003457 
SFLT-1 -0.09135 0.008344 0.4454 0.04022 0.001618 0.7373 
SICAM-1 0.05467 0.002989 0.6483 -0.2917 0.08507 0.01292 
SVCAM-1 0.02821 0.0007958 0.814 -0.03917 0.001534 0.7439 
TARC 0.03566 0.001271 0.8161 -0.1504 0.02261 0.2873 
TIE-2 -0.006862 4.708e-05 0.9544 NA NA NA 
TNF α -0.1077 0.0116 0.3679 NA NA NA 
VEGF 0.1595 0.02544 0.1808 -0.1687 0.02845 0.1567 
VEGF-C 0.03197 0.001022 0.7898 NA NA NA 
VEGF-D -0.1783 0.03179 0.134 -0.06774 0.004588 0.6134 
Supplementary table 3 
Fluid Biomarker CSF tau CSF p-tau CSF  Aβ1-42 
r2 p r2 p r2 p 
CSF CRP 0.0003235 0.846 0.001865 0.6409 0.00955 0.2904 
CSF IL_12/IL_23P40 0.01226 0.2306 0.009082 0.3026 0.03764 0.0345 
CSF IL-15 0.2654 2.039e-09 0.245 1.05e-08 0.002249 0.6086 
CSF IL-16 0.01716 0.1556 0.01479 0.1877 0.001367 0.6897 
CSF IL-6 0.0002887 0.8551 0.001645 0.6628 0.01254 0.2273 
CSF IL-7 0.001604 0.7243 0.01029 0.3706 0.006242 0.486 
CSF IL-8 0.02897 0.06421 0.01471 0.1889 0.01402 0.1997 
CSF IP-10 0.006924 0.3683 0.005959 0.404 0.002767 0.5699 
CSF MCP-1 0.1621 5.649e-06 0.142 2.397e-05 0.05423 0.01082 
CSF MCP-4 0.02436 0.2791 0.01007 0.488 0.02086 0.3169 
CSF MDC 0.003253 0.6971 0.001118 0.8196 8.665e-05 0.9494 
CSF MIP-1A 0.001327 0.7176 0.002558 0.6155 0.0008347 0.7743 
CSF MIP-1B 0.02877 0.06515 0.03654 0.0373 0.00127 0.7004 
CSF PIGF-1R 0.01279 0.2207 0.005253 0.4335 0.03163 0.05299 
CSF SAA 0.0004854 0.812 0.0003939 0.8304 0.003962 0.4965 
CSF SFLT-1 0.3742 1.461e-13 0.3159 2.921e-11 0.007829 0.3386 
CSF SICAM-1 0.2159 1.022e-07 0.1608 6.2e-06 0.004468 0.4701 
CSF SVCAM-1 0.2576 3.847e-09 0.1971 4.252e-07 0.007408 0.352 
CSF TARC 0.009188 0.3977 0.01015 0.3739 0.01018 0.3732 
CSF VEGF 0.01739 0.1528 0.01547 0.1777 0.03451 0.04311 
CSF VEGF-D 0.1766 1.824e-05 0.1369 0.000191 0.000304 0.8654 
SERUM bFGF 0.008102 0.3431 0.01401 0.2118 0.0006154 0.7942 
SERUM CRP 0.0007429 0.7695 2.133e-05 0.9604 0.02808 0.06974 
SERUM EOTAXIN 0.03644 0.09197 0.06677 0.02149 0.07626 0.01376 
SERUM EOTAXIN-3 0.02447 0.2134 0.06269 0.04425 0.01563 0.321 
SERUM IFN-G 0.01741 0.158 0.01226 0.2368 0.004118 0.4937 
SERUM IL-12/IL-23P40 0.001056 0.7268 1.358e-05 0.9684 2.732e-05 0.9552 
SERUM IL-15 0.004106 0.4925 1.726e-05 0.9645 0.0009366 0.7433 
SERUM IL-16 0.004112 0.4903 0.01189 0.2398 0.0001476 0.8961 
SERUM IL-6 0.001357 0.7726 0.02911 0.1776 0.016 0.3192 
SERUM IL_7 0.003842 0.5049 0.000976 0.737 0.002625 0.5816 
SERUM IL_8 0.01972 0.1294 0.09044 0.0009367 0.004297 0.4806 
SERUM IP_10 0.01147 0.3476 0.001015 0.7805 0.0005459 0.8381 
SERUM MCP_1 0.03958 0.0788 0.01902 0.2255 0.007945 0.4347 
SERUM MCP_4 0.02464 0.1671 0.01643 0.2602 0.0002622 0.8874 
SERUM MDC 0.02151 0.1972 0.02478 0.1659 0.07169 0.01705 
SERUM MIP_1A 0.0002669 0.9023 0.009841 0.4547 0.02668 0.2164 
SERUM MIP_1B 0.001628 0.7241 4.15e-05 0.9551 0.01484 0.2848 
SERUM PIGF-1R 0.05444 0.011 0.03007 0.06039 0.001453 0.6819 
SERUM SAA 0.005115 0.4415 0.00115 0.7154 0.0155 0.1791 
SERUM SFLT-1 0.01064 0.2664 0.001217 0.7077 0.002335 0.6033 
SERUM SICAM-1 0.002597 0.5836 0.001625 0.6647 0.02377 0.09552 
SERUM SVCAM-1 0.01487 0.1883 0.02065 0.1205 0.03433 0.04457 
SERUM TARC 0.002146 0.6852 0.001686 0.7194 0.004668 0.5497 
SERUM TIE-2 0.001901 0.6392 6.178e-07 0.9933 0.03242 0.05104 
SERUM TNF-A 0.007494 0.3513 0.001869 0.6421 0.002515 0.5897 
SERUM VEGF 0.0024 0.5983 0.005749 0.4145 0.0113 0.252 
SERUM VEGF-C 0.00106 0.7263 0.002456 0.594 0.009107 0.304 
SERUM VEGF-D 0.05526 0.01039 0.0391 0.03184 0.02879 0.06625 
(a) 
(b) 

  
Supplementary Figure  – ROC curves of the serum (a) and CSF (b) models predictive of 
biomarker CSF profile in subjects with cognitive impairment. 
The ROC curves of the LASSO models including neuroinflammatory biomarkers (in red) are 
compared with the ROC curves of the reference LASSO models (in blue) in the sub-
population of 72 subjects with cognitive impairment (CDR > 0). The opacity of the curves is 
proportional to the accuracy of the models. The diamonds indicate the selected most accurate 
models. The p-values on the graphs indicate the significance of the differences of AUC. The 
biomarkers models had a ROC AUC of 0.96 [0.89 – 0.99] in serum and 0.93 [0.85 – 0.97] in 
CSF. 
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HIGHLIGHTS: 
- Distinct serum and CSF inflammation signatures are associated with AD pathology. 
- Serum and CSF inflammation markers improve the classification accuracy for AD. 
- Six CSF inflammation markers were associated with tau pathology and neuronal 
injury. 
